Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with curative intent
Michela Buglione et al.
LUNG CANCER (2020)
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Anne-Marie C. Dingemans et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer
Sabrina Rossi et al.
FUTURE ONCOLOGY (2019)
Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)
D. Raben et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Xin Li et al.
THORACIC CANCER (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
Bo Qiu et al.
CLINICAL LUNG CANCER (2017)
The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis
O. S. H. Chan et al.
CLINICAL ONCOLOGY (2017)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez et al.
LANCET ONCOLOGY (2016)
The cellular origins of drug resistance in cancer
Geoffrey R. Oxnard
NATURE MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications
David R. Gandara et al.
CLINICAL LUNG CANCER (2014)
Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib
Gregory N. Gan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer
Puneeth Iyengar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
Antonio Rossi et al.
LANCET ONCOLOGY (2014)
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
Takehito Shukuya et al.
LUNG CANCER (2011)
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis
Kyle E. Rusthoven et al.
ACTA ONCOLOGICA (2009)
Resection of adrenal metastases from non-small cell lung cancer: A multicenter study
H Porte et al.
ANNALS OF THORACIC SURGERY (2001)
Share Paper
